Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3 million Cash runway extended into...
Brain
Long-time Collaborators Botond Roska and José-Alain Sahel Win International Prize for Translational Neuroscience
J-A. Sahel (left)_B.Roska (right) J-A. Sahel (left)_B.Roska (right)Basel, Switzerland, June 22, 2023 --In recognition of their pioneering work on restoring...
Appointment of Dr. Christopher von Jako as new CEO
Durham, N.C., June 21, 2023 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), the medical imaging company, announces that the...
Lumos to Highlight New LUM-201 Data and Analysis Presented at ENDO 2023 in Virtual KOL Webinar
Webinar to Review Data Demonstrating Potential Drug Effect and Durable Response Webinar to be held Today June 21, 2023 at...
HMNC Brain Health to Participate in the Psychedelic Science Conference 2023 and the H.C. Wainwright & Co. 4th Annual Neuropsychiatry Conference
MUNICH, Germany, June 21, 2023 (GLOBE NEWSWIRE) -- HMNC Brain Health (“HMNC” or the “company”), a global clinical-stage biopharmaceutical company,...
Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants
Research grants from U.S. Department of Defense (DoD) and National Cancer Institute’s Research Project Grant (NCI R01) awarded to UTHSC...
Ocean Biomedical (NASDAQ: OCEA) Announces Share Price Target Increase to $17.63 by Fundamental Research Corp. on Positive Results from Independent Study Showing Glioblastoma Tumor Suppression, Received Patents, and Recent Financing
Providence, RI, June 21, 2023 (GLOBE NEWSWIRE) -- Ocean Biomedical, Inc. (NASDAQ: “OCEA”), a next-generation biopharma company working to accelerate the...
BrainsWay Announces Significant Expansion in Western and Central U.S.
30 Deep TMS™ Devices Ordered by Large Mental Health-Focused TMS NetworkBURLINGTON, Mass. and JERUSALEM, June 21, 2023 (GLOBE NEWSWIRE) --...
uniQure Announces Update on U.S. Phase I/II Clinical Trial of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
Change in Total Motor Score June 2023 Webcast Presentation Neurofilament Light Chain (Nfl) percentage change from baseline in Cerebrospinal Fluid...
Relievant Medsystems Announces Favorable Coverage Policy from Cigna Healthcare for the Intracept Procedure
MINNEAPOLIS, June 20, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic...
ADvantage Therapeutics Secures Approvals for Clinical Trial of AD04™ in Alzheimer’s Disease Treatment in Poland, Bulgaria, and Slovakia
MIAMI, June 20, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for...
PaxMedica CEO Interviewed by The BRAIN Foundation
Webcast Link Available at PaxMedica.com TARRYTOWN, NY, June 20, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – PaxMedica, Inc. (Nasdaq: PXMD),...
HMNC Brain Health Begins Phase 2 Study for Personalized Treatment of Stress-Axis Related Major Depressive Disorder (MDD)
The Company’s Nelivabon Program Pairs Novel Compound with Companion Diagnostics to Treat MDD patientsMUNICH, Germany, June 20, 2023 (GLOBE NEWSWIRE)...
Appeal of Delisting Determination
20 June 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage...
Axial Therapeutics Receives Second Research Grant Award from The Michael J. Fox Foundation to Further Support Advancement of AX-5006 for Parkinson’s Disease
–Grant supports the continued preclinical development of AX-5006, a small molecule, gut-restricted amyloid inhibitor for symptomatic treatment and modification of...
Cognition Therapeutics Invited to Participate on Panel During Cantor Fitzgerald Brain Week 2023 on Novel Alzheimer’s Disease Approaches
PURCHASE, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that...
Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023
-- Mean BMI reduction of 21.0% from baseline observed in 13 patients at six months, showing progression from 16.8% mean...
vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline
vTv discovered small molecule RAGE inhibitor is being developed by Cantex under worldwide development and commercialization agreementHIGH POINT, N.C., June...
Relievant Medsystems Announces Pooled Three-Year Outcomes from Intracept Procedure that Demonstrate Long-Term Pain Relief and Reduced Opioid Use in Chronic Vertebrogenic Low Back Pain Patients
MINNEAPOLIS, June 15, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic...
Results of Annual General Meeting and General Meeting
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting and General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or...